drugset / Trial / NCT03906357
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Expanded access
No longer available
Incyte Corporation
H. Lee Moffitt Cancer Center and Research Institute · collab
Summary
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | — | — |
Indications
No indication recorded.